Published 10 days ago • loading... • Updated 10 days ago

Neurotech inks European development deal for cannabinoid therapies

Summary by Stockhead

Neurotech enters partnership agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company Development agreement to enable Neurotech to expand into new markets Neurotech looks to scale production to meet future product demand upon regulatory approvals Special Report: Neurotech International has inked a deal with a European leader in development and scale up of cannabis-based products for pharmaceutical use as it eyes Australi…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Stockhead

Neurotech inks European development deal for cannabinoid therapies

10 days ago

Read Full Article

sharecafe.com.au

Neurotech partners with RH Pharma for cannabinoid therapy development

Neurotech International (ASX: NTI) has signed a development agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC), to produce a pharmaceutical-grade, broad-spectrum cannabinoid drug for paediatric neurodevelopmental disorders. The collaboration will leverage RH Pharma’s proprietary CO2 extraction technology and Good Manufacturing Practice (GMP) capabilities to create a strain-agnostic drug product that…

10 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right